PLAQUENIL
Total Payments
$128,165
Transactions
14
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $37,287 | 1 | 0 |
| 2022 | $18,022 | 4 | 0 |
| 2021 | $2,401 | 2 | 0 |
| 2020 | $70,455 | 7 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $128,165 | 14 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19 | SANOFI US SERVICES INC. | $128,165 | 0 |
Top Doctors Receiving Payments for PLAQUENIL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Tampa, FL | $128,165 | 14 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $128,165
Product Information
- Type Drug
- Total Payments $128,165
- Total Doctors 0
- Transactions 14
About PLAQUENIL
PLAQUENIL is a drug associated with $128,165 in payments to 0 healthcare providers, recorded across 14 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2020 to 2023. In 2023, $37,287 was paid across 1 transactions to 0 doctors.
The most common payment nature for PLAQUENIL is "Unspecified" ($128,165, 100.0% of total).
PLAQUENIL is associated with 1 research study, including "A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19" ($128,165).